" class="no-js "lang="en-US"> Pillar Biosciences Announces Appointment of Randy Pritchard as Chief Executive Officer - Medtech Alert
Friday, June 14, 2024

Pillar Biosciences Announces Appointment of Randy Pritchard as Chief Executive Officer

Pillar Biosciences, an innovative next-generation sequencing (NGS) solutions in-vitro diagnostics (IVD) company, today announced the appointment of Randy Pritchard as Chief Executive Officer. The company’s founder, industry veteran and renowned scientific innovator, Gang Song, Ph.D., will transition to the role of Chairman of the Board, where he will be responsible for leading the Board, ensuring governance standard and focusing on all strategic matters for Pillar Biosciences. In his new role as CEO, Mr. Pritchard will look to accelerate the company’s efforts to make precision oncology accessible for all patients throughout the patient journey.

Mr. Pritchard brings to Pillar Biosciences more than 24 years of healthcare experience, as a diagnostics executive who has deep experience in corporate and commercial strategy, sales and marketing, driving growth through innovation. He has held positions of increasing responsibilities, including SVP of US Diagnostics marketing, SVP & Lifecycle Leader at the divisions of POC Diagnostic & Core Reagents, and VP of Marketing at Centralized Diagnostics at Roche Diagnostics.

“On behalf of the Board, I am excited to welcome Randy to lead Pillar Biosciences in its next stage of growth. He brings invaluable experience, as we accelerate our growth with the launch of our oncoReveal™ Dx Lung and Colon Cancer Assay, which received FDA Premarket Approval recently,” said Gang Song, Ph.D., Co-Founder and Chairman of the Board, Pillar Biosciences. “Pillar Biosciences was founded with a mission to make precision medicine accessible for all, by simplifying clinical next-generation sequencing (NGS) and bringing testing closer to the patient.”

“The Board was impressed by Randy’s depth of understanding of the diagnostics space and what drives growth, as well as his leadership experience,” said Simone Song, Founder, ORI Capital who has led repeated investments in Pillar Biosciences since its Series A financing. “His ability to quickly analyze a business, develop and execute on the growth strategy was truly remarkable. I am fully confident that Randy will be an outstanding leader for Pillar at this next stage of growth.”

“I look forward to working with Gang and the Pillar Biosciences team to accelerate the adoption of oncoReveal™ Dx and bring more innovative NGS cancer testing products to patients, in particular in the area of liquid biopsy,” said Randy Pritchard, CEO, Pillar Biosciences. “Pillar has grown to over 150 dedicated team members in the US and China, and I look forward to leading the company in its next stage of growth to become a global clinical cancer NGS diagnostics company.”

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more